Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole. - Wikidata - awgldk - TriplyDB

Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.

Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.

http://www.wikidata.org/entity/Q37274678

about

Effect of Native Gastric Mucus on in vivo Hybridization Therapies Directed at Helicobacter pylori.Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole.Pulmonary penetration of piperacillin and tazobactam in critically ill patients.Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.Extensively drug-resistant Acinetobacter baumannii in a Thai hospital: a molecular epidemiologic analysis and identification of bactericidal Polymyxin B-based combinations.Penetration of vancomycin into epithelial lining fluid in healthy volunteers.Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention.Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives.Penetration of Ceftaroline into the Epithelial Lining Fluid of Healthy Adult Subjects.Tissue penetration of antifungal agents.Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents.Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.Pharmacokinetics of Cefuroxime in Synovial Fluid.Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients

P2860

Q27317349-7B41C5B4-3F26-4837-90AF-611F3D9FEFB3 Q28066877-968A8F9D-B080-42E2-A05A-D86766A2689C Q28085517-3A5EFB41-8C23-47AC-B3AB-77F53C4B8FA2 Q34151060-BD45DBE8-56B0-4D5D-8D4C-48E4381B2070 Q34187667-A1E94A70-0B09-4113-A7ED-C0A173120046 Q34216623-079A9C67-55A9-460E-B544-69D14694707E Q34433342-D15F91AB-D69B-428C-AD11-49D9DE2D18A5 Q35041371-7E35A5BF-449C-452B-A4B8-F4A1AB5C3656 Q35598408-559DDE0D-88C7-4229-A6C5-BA2935BDF1D9 Q35666434-A3B4BEDD-A2D8-4202-84A1-9BAC91864BD6 Q37258271-D2759E74-70F0-41A6-8166-93094BF68587 Q37259653-50F296FE-5CAC-4C62-9D27-9459B5970200 Q37287884-E1FC780C-B378-471E-B6EF-ECE5B9B34601 Q37544911-2BB19F46-2F76-4236-B85E-8ADF81A0C7D1 Q37927017-B475294D-EA02-4060-BCF8-8E6179313E2D Q37942644-862425AE-CEBF-4823-B704-16EE0A81199B Q37955286-E080EFDA-7D96-4EE8-A4F4-DEFB878A4AD8 Q39164183-66B9672B-AD76-4721-BF2B-8AD0FE7DB383 Q47265801-14A3EF91-5E6B-4B0C-9808-8078B1CA9BB5 Q58701649-F701415C-4692-457B-A17A-DEC273D0F29D

P2860

Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.

http://www.wikidata.org/entity/Q37274678

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.

@en

Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.

@nl

type

label

Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.

@en

Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.

@nl

prefLabel

Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.

@en

Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.

@nl

P1433

Q37274678-17C9D32A-8484-40EE-BAD0-912A64ADEF18

P1476

Q37274678-4B5321D9-A3E3-40D4-8DEE-0564DD6A6DDA

P2093

Q37274678-05A2A3F0-4D2F-4CAA-A277-15597537BF87

Q37274678-1CFD9491-40A4-40CF-9D83-C10D7E2C4381

Q37274678-24DB5882-8670-4BFB-AEE1-45818C55D771

Q37274678-441397C6-B337-4CFA-944B-E217D82A7A70

Q37274678-4BF01CF6-D0A8-4F27-AFD5-3BFC838A9BE3

Q37274678-69A0B151-18CB-44DF-A890-EB2F6185A728

Q37274678-70E0AAEF-6503-4763-B5DF-130AE19D8730

Q37274678-7403FA21-385D-4A25-B903-8775309FB470

Q37274678-97343AB7-18A6-470B-BE14-1229577ED0B5

Q37274678-C12BF9D3-482B-45F9-AAC3-62FB7CC123F3

P2860

Q37274678-1260B0E6-4BAE-4BAA-8D4B-F173A2F147B6

Q37274678-2C677573-CCDE-43B3-8073-E371C2550918

Q37274678-31A10E0D-80C1-48D3-BCA2-4C59446F6788

Q37274678-380C585E-87A3-42A2-92E8-022A597E354B

Q37274678-388270E3-FA8C-429C-AA40-7FB56EFCD5F8

Q37274678-57C42149-C181-4059-A7BC-0D29D7414611

Q37274678-7CE0EF32-9E0E-497F-A21C-A0CFE4AA419F

Q37274678-B14B553C-FB90-428D-9115-7967397E4BD1

Q37274678-B610A1D6-8783-4D83-A400-14C92F920EC3

Q37274678-C757892A-5C64-4490-821C-D35EC8B053BD

P304

Q37274678-A88949FB-61D0-4C3F-8869-B8CF174A4763

P31

Q37274678-F984B523-511B-4A0D-AEC5-7EE7820A362D

P356

Q37274678-6B5AA575-DE16-45F2-91C6-A9CC7772AE4A

P407

Q37274678-8F13DDE1-D096-44ED-A1B8-D1FDA720C727

P433

Q37274678-400E5F65-E4CB-4564-AA8E-C9FCEB62EA0B

P478

Q37274678-7D210A30-D89C-48AE-A581-2C9A2CAA79A3

P577

Q37274678-0DDDE34D-D460-453F-82AA-2D14CDD6D656

P698

Q37274678-B86DA351-E64A-4A91-A0EB-78339DFA1BC3

P921

Q37274678-EF211C89-69A9-411E-9EED-1EC3F9E5A1E7

P932

Q37274678-20063566-97B6-418D-8C8B-EA4F73443929

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.

@en

P2093

David P Nicolau

http://www.w3.org/2001/XMLSchema#string

G L Drusano

http://www.w3.org/2001/XMLSchema#string

Gary J Noel

http://www.w3.org/2001/XMLSchema#string

James B Kahn

http://www.w3.org/2001/XMLSchema#string

Keith A Rodvold

http://www.w3.org/2001/XMLSchema#string

Mark Gotfried

http://www.w3.org/2001/XMLSchema#string

Mohammed Khashab

http://www.w3.org/2001/XMLSchema#string

Pamela R Tessier

http://www.w3.org/2001/XMLSchema#string

Sara A Murray

http://www.w3.org/2001/XMLSchema#string

Somvadee Laohavaleeson

http://www.w3.org/2001/XMLSchema#string

P2860

Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.

Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat.

Epidemiology, treatment, and prevention of community-acquired methicillin-resistant Staphylococcus aureus infections.

Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains

In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models

Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation.

Intrapulmonary concentrations of telithromycin: clinical implications for respiratory tract infections due to Streptococcus pneumoniae.

Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia.

Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia.

Comparison of 99mTc-DTPA and urea for measuring cefepime concentrations in epithelial lining fluid.

P304

3294-3301

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00144-09

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19451287

http://www.w3.org/2001/XMLSchema#string

P921

P932

2715607

http://www.w3.org/2001/XMLSchema#string